LEO Pharma Puts Patients at the Heart of Innovation
3/19/2013 10:14:23 AM
More...
|
Virobay Inc. and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3/18/2013 10:12:23 AM
More...
|
LEO Pharma Receives FDA Approval for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for Body Plaque Psoriasis
10/26/2012 12:40:41 PM
More...
|
LEO Pharma Initiates Global Search for New Partners
6/14/2012 11:41:06 AM
More...
|
LEO Pharma Release: The New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses
3/15/2012 9:48:56 AM
More...
|
LEO Pharma Debuts Patient Assistance Program for Plaque Psoriasis Patients
3/6/2012 9:33:14 AM
More...
|
American Academy of Dermatology and LEO Pharma Launch Educational Website to Raise Awareness About Sun Damage and Skin Cancer
2/15/2012 2:28:07 PM
More...
|
LEO Pharma Sales Reps File Overtime Class Action in New York Federal Court
2/9/2012 8:47:47 AM
More...
|
FDA Approves LEO Pharma's Picato® (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
1/25/2012 7:33:32 AM
More...
|
LEO Pharma Debuts LEO® Quality Care Program for Plaque Psoriasis Patients
1/11/2012 8:58:06 AM
More...
|
|